Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059942 | 0.85 | KDM4E (0.61) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL4446531 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL4441865 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL8199168 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL1856986 | 0.81 | PIK3CA (0.52) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL4434053 | 0.80 | PIK3CA (0.50) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL1860340 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL189813 | 0.78 | PIK3CA (0.49) | SMN1; SMN2ALDH3A1ALDH1A3PIK3CAPIK3CB | |
| SCHEMBL4068550 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL1859364 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101909631-B | Process for making thienopyrimidine compounds | GENENTECH INC | 2012-09-12 | — | — | CN | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-11603372-B2 | Compounds and therapeutic uses thereof | VIOGEN BIOSCIENCES, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2021-04-29 | — | — | US | disclosed |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2021-04-29 | — | — | US | disclosed |
| WO-2019113523-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | BAJJI ASHOK (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113523-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | BAJJI ASHOK (US) | 2019-06-13 | — | — | WO | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007122410-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 3575/4885KDM4E 1752/4885ALDH1A1 1766/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | SMN1; SMN2 1774/4885KDM4E 3626/4885ALDH1A1 2960/4885 |
| US-11603372-B2 | Compounds and therapeutic uses thereof | IL15, IL17A, IL2 | SMN1; SMN2 1341/4885KDM4E 3881/4885ALDH1A1 1513/4885 |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | IL15, IL17A, IL2 | SMN1; SMN2 1341/4885KDM4E 3881/4885ALDH1A1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.